Scientists have taken another big step forward towards developing a vaccine that’s effective against the most severe forms of malaria.
Professor Denise Doolan from James Cook University’s Australian Institute of Tropical Health and Medicine (AITHM) was part of an international team that narrowed down the malaria proteins and disease-fighting antibodies that could be used to develop a vaccine against severe malaria.
She said according to the latest figures from the World Health Organisation, there were 219 million cases of malaria worldwide in 2017, leading to an estimated 435,000 deaths.
“What makes this work so difficult is the particular survival strategy of the malaria parasite in the human body. It grows within blood cells and inserts proteins into the surface of the blood cell so it sticks to the walls of blood vessels,” Professor Doolan said.
“But it changes these proteins to escape from immune responses, and every strain has a different set of proteins, making the identification of vaccine targets extraordinarily hard.”
The team of collaborators – involving JCU, the Walter and Eliza Hall Institute of Medical Research (WEHI) at Deakin University, and malaria experts from Papua New Guinea, France and the USA – collected hundreds of PfEMP1 proteins from malaria strains from children in PNG who had been naturally infected by the disease, made a custom protein microarray of those strains, and then examined serum samples to identify which of the many PfEMP1 variants were associated with protection.
The research team managed to pinpoint which antibodies were most effective in fighting the most severe forms of malaria.
Associate Professor Alyssa Barry, who leads the Systems Epidemiology of Infection unit within the Deakin School of Medicine, said the findings from the project were a major step towards developing a viable vaccine for the disease.
“It’s the first time anyone has shown this – for years, researchers have thought that developing a malaria vaccine based on PfEMP1 would be virtually impossible, because the proteins are just so diverse,” Associate Professor Barry said.
“It’s similar to the flu vaccine, where you have to keep adjusting and updating it as the virus strains evolve from year to year. Malaria is even more diverse than influenza – one village in a country such as PNG could contain thousands of possible malaria strains. But in malaria-endemic areas, children who are repeatedly infected develop immunity to severe malaria by the time they’re about two years old, so we know antimalarial immunity is possible, and it can develop after exposure to only a few strains.”
Associate Professor Barry said while immunity to milder forms of malaria presented a “formidable obstacle”, immunity to severe malaria targets only a small subset of proteins that have many similarities between strains – making the essential components for a vaccine much easier to identify.
“Using genomic sequencing, we collected PfEMP1 proteins from different strains of malaria, measured antibodies to those proteins and then used machine learning to identify the protective antibody – the biomarker of immunity – that protects kids against disease,” she said.
“We were able to identify these antibodies by monitoring for patterns of disease, following the children in PNG for 16 months to determine which of them were susceptible to the more severe forms of the disease, and those who were protected and only experienced milder forms of the disease.
“It’s been a long road, and has involved a large team, but it’s a major step forward, and this provides hope that creating a vaccine might be possible.”
The full research findings, “Protective immunity against severe malaria in children is associated with a limited repertoire of antibodies to conserved PfEMP1 variants”, were published today in the scientific journal Cell Host & Microbe.
Learn more: Scientists close in on malaria vaccine
The Latest on: Malaria
- Taiwan Liposome on go with study of inhalable malaria drug for COVID-19; shares up 32%on October 7, 2020 at 7:07 am
Thinly traded micro cap Taiwan Liposome Company (TLC +31.7%) jumps on an 8x surge in volume in reaction to regulatory sign-offs in Australia and Taiwan to launch a Phase 1 clinical trial evaluating ...
- Togo: Malaria Consortium Expands Seasonal Malaria Chemoprevention to Togoon October 7, 2020 at 6:55 am
Malaria Consortium is pleased to announce the expansion of its seasonal malaria chemoprevention (SMC) programme to support implementation in Togo. Bringing extensive experience of SMC delivery, ...
- Nigeria: Malaria - 90% of Life-Saving Interventions Still On Track - Officialon October 7, 2020 at 1:42 am
Despite challenges posed by the COVID-19 pandemic, over 90 per cent of life-saving malaria intervention campaigns scheduled for this year are still on track.
- Taiwan Liposome secures Australian and Taiwan approval to initiate trial of inhaled malaria drug for COVID-19on October 6, 2020 at 9:35 pm
(NASDAQ:TLC) has received ethical and scientific approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its Phase I clinical trial of TLC19 Hydroxychloroquine Liposome ...
- Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosison October 6, 2020 at 6:14 am
The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule ...
- Experts say Africa must scale-up malaria protection for pregnant womenon October 5, 2020 at 7:21 pm
Amidst the COVID-19 pandemic in sub-Saharan Africa, malaria - one of the world’s oldest diseases - is impacting disproportionately on pregnant women and children aged under five ...
- Understanding how the malaria parasite can withstand fever's heaton October 5, 2020 at 3:30 pm
Even when a person suffering from malaria is burning up with fever and too sick to function, the tiny blood-eating parasites lurking inside them continue to flourish, relentlessly growing and ...
- How malaria parasites withstand a fever's heaton October 5, 2020 at 1:04 pm
The parasites that cause 200 million cases of malaria each year can withstand feverish temperatures that make their human hosts miserable. Now, a Duke University-led team is beginning to understand ...
- Global Fund and Chevron: United Against HIV, TB and Malariaon October 5, 2020 at 2:47 am
English News and Press Release on Nigeria and 6 other countries about Contributions, HIV/Aids and Epidemic; published on 05 Oct 2020 by Global Fund ...
- Malaria Cases Spike In Northern Malion October 3, 2020 at 6:16 am
Malaria cases in northern Mali have spiked, according to medical workers, claiming 23 lives in the often lawless desert region last week alone.
via Bing News
The Latest on: Malaria vaccine
- 65,000 children to get final malaria vaccine dose next Februaryon October 4, 2020 at 1:20 pm
Children aged 6-24 months are expected to get four doses at six, seven, nine and 24 months through an injection on the upper arm ...
- Life-Saving Malaria Campaigns On Track In The Majority Of Malaria-Affected Countries Despite Covid-19on October 2, 2020 at 5:43 am
New data confirms that over 90% of life-saving malaria intervention campaigns scheduled for this year are on track across Africa, Asia and the Americas ...
- Vaccines Market 2020: Global Analysis by Top Manufacturers with Size, Share, Segments, Industry Drivers and Challenges by 2026on September 29, 2020 at 2:42 am
The global “Vaccines Market Size” is expected to be USD 93.08 billion by 2026, exhibiting a CAGR of 10.7% during ...
- At 33.2% CAGR, Malaria Vaccines Market Size is Expected to Exhibit 134.9 Mn US$ by 2026on September 25, 2020 at 8:45 am
Selbyville, Delaware: The 2019-2026 report on Malaria Vaccines Market explores the essential factors Of Mobility ...
- East Africa: People With This Blood Type Are Unlikely to Get Malariaon September 22, 2020 at 5:00 pm
The study shows the blood group variant called Dantu protects against severe malaria, information that could boost therapies and vaccines. The research is by Kemri-Wellcome Trust in Kilifi ...
- Race to find Covid-19 vaccine puts spotlight on big 3 of infectious diseaseson September 16, 2020 at 1:03 am
It also reminds us of the importance of vaccine research for the many other infectious parasites, viruses and bacteria that can cause disease and death. Malaria is a parasitic disease transmitted ...
- Injectable hydrogel could someday lead to more effective vaccineson September 15, 2020 at 5:00 pm
However, vaccines against some diseases, including HIV-1, influenza and malaria, don't work very well, and one reason could be the timing of antigen and adjuvant presentation to the immune system.
- Bill Gates: “Our values do change what gets funded in this economy”on September 15, 2020 at 12:04 am
That includes reduction in new cases of malaria, and universal health care and vaccinations. Bill Gates has made vaccine development and distribution a priority for over a decade. He has put more ...
- Malaria vaccines: A Toy for Travelers or a Tool for Eradication?on September 14, 2020 at 5:00 pm
EMVI = European malaria vaccine initiative; GLURP = Glutamate-rich protein; GSK = GlaxoSmithKline; LSA = Liver-stage antigen; LSP = Long-synthetic peptide; ME-TRAP = Multiepitope-thrombospondin ...
- WHO welcomes preliminary results of Malaria vaccine trialson September 9, 2020 at 4:59 pm
The World Health Organization’s Regional Office for Africa has welcomed the announcement that trials of a malaria candidate vaccine shows promising results by providing protection against clinical ...
via Bing News